Get Live Data

Adrian Hargrave, CEO of SEEEN, explains how the Company is now funded through to profitability.  Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. Lord John Hutton steps down from Board of Directors

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Lord John Hutton steps down from Board of Directors

31 May 2018 14:00

Arix Bioscience Plc - Lord John Hutton steps down from Board of Directors

Arix Bioscience Plc - Lord John Hutton steps down from Board of Directors

PR Newswire

London, May 31

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

LONDON, 31 May 2018: Arix Bioscience plc (LSE: ARIX) (“Arix” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Lord Hutton is stepping down from his position as a Non-Executive Director of Arix Bioscience.

Jonathan Peacock, Chairman of Arix Bioscience, said: “It has been a great pleasure to work with Lord Hutton over the last two years. He has been an invaluable guide to me and to the Board as we have built Arix Bioscience and we will all miss his wise counsel and support. He leaves with our thanks and very best wishes.”

For more information, please contact:

Arix Bioscience plcCharlotte Parry, Investors Relations Manager+44 (0) 20 7290 1072Charlotte@arixbioscience.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

3456789101112
Date   Source Headline
11th Dec 20197:05 amPRNIterum announces topline Phase 3 data
9th Dec 20197:01 amPRNAutolus announces new AUTO3 data at ASH
9th Dec 20197:00 amPRNAutolus announces key new data at ASH
22nd Nov 20199:57 amPRNHolding(s) in Company
21st Nov 201912:06 pmPRNHarpoon and AbbVie announce licensing and option deal
7th Nov 201912:22 pmPRNAutolus reports Q3 2019 financial results
7th Nov 20197:22 amPRNChange of Broker
6th Nov 20192:31 pmPRNAutolus to present new data at the ASH Annual Meeting
6th Nov 20197:02 amPRNArtios expands DDR pipeline with new asset
17th Oct 20191:40 pmPRNHolding(s) in Company
16th Oct 20198:00 amPRNAura reports updated Phase 1b/2 clinical data for AU-011
15th Oct 20193:20 pmPRN]Holding(s) in Company
3rd Oct 20197:06 amPRN2019 Capital Markets Day
2nd Oct 20197:00 amPRNManagement change
30th Sep 20197:00 amPRNArix co-leads EUR 20m Series A financing in STipe
17th Sep 20197:47 amPRNAmplyx unveils expanded pipeline and Phase 2 data
28th Aug 20197:00 amPRNInterim results for the six months ended 30 June 2019
20th Aug 20197:25 amPRNNotice of Results
8th Aug 20191:03 pmPRNAutolus reports Q2 2019 financial results
1st Aug 20197:00 amPRNTotal Voting Rights
8th Jul 20193:34 pmPRNHolding(s) in Company
3rd Jul 20197:00 amPRNIssue of Ordinary Shares, TVR, PDMR Notifications
28th Jun 20193:22 pmPRNHolding(s) in Company
25th Jun 20194:17 pmPRNHolding(s) in Company
18th Jun 20195:23 pmPRNHolding(s) in Company
3rd Jun 20195:51 pmPRNCorrection: Result of AGM
3rd Jun 20195:16 pmPRNResult of AGM
3rd Jun 20197:00 amPRNTotal Voting Rights
10th May 20197:00 amPRNDirector/PDMR Shareholding
1st May 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
16th Apr 20197:00 amPRNAutolus announces closing of public offering
11th Apr 20197:00 amPRNAutolus announces pricing of public offering
9th Apr 20197:00 amPRNAutolus announces launch of proposed public offering
2nd Apr 20197:08 amPRNAura completes $40 million Series D financing
1st Apr 20196:10 pmPRNAutolus presents initial AUTO1 data at AACR
28th Mar 20197:00 amPRNAnnual Results for the year ended 31 December 2018
28th Mar 20197:00 amPRNBoard changes
26th Mar 201910:17 amPRNAutolus hosts R&D day and provides update on AUTO3
20th Mar 201912:23 pmPRNNotice of Results
18th Mar 20197:00 amPRNArix co-leads $63m Series B investment round for Imara
19th Feb 201912:12 pmPRNAutolus announces updated results from CARPALL trial
19th Feb 20197:00 amPRNManagement and Board changes
14th Feb 20197:00 amPRNHarpoon closes initial public offering
8th Feb 20197:09 amPRNHarpoon prices Nasdaq IPO
1st Feb 201910:38 amPRNTotal Voting Rights
29th Jan 20192:25 pmPRNUpdate on Harpoon proposed IPO in the United States
3rd Jan 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
28th Dec 20187:00 amPRNHarpoon announces proposed public offering in the US
11th Dec 20187:00 amPRNArix appoints Dr Christian Schetter as EIR
3rd Dec 20187:00 amPRNAutolus presents initial AUTO3 clinical data at ASH
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.